Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

[1]  G. Ball,et al.  Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer , 2014, Molecular oncology.

[2]  G. Ball,et al.  DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts , 2014, Molecular oncology.

[3]  G. Jena,et al.  3-Aminobenzamide – a PARP inhibitor enhances the sensitivity of peripheral blood micronucleus and comet assays in mice , 2014, Toxicology mechanisms and methods.

[4]  A. Paradiso,et al.  Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer , 2014, Cell Death and Disease.

[5]  Cheng Lu,et al.  Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis , 2013, Breast Cancer Research and Treatment.

[6]  G. Ball,et al.  Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy , 2013, Breast Cancer Research and Treatment.

[7]  Samuel H. Wilson,et al.  Interaction between DNA Polymerase β and BRCA1 , 2013, PloS one.

[8]  George Iliakis,et al.  DNA double-strand–break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice , 2013, Nucleic acids research.

[9]  C. Seedhouse,et al.  Clinicopathological and functional significance of XRCC1 expression in ovarian cancer , 2013, International journal of cancer.

[10]  Y. Shiloh,et al.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more , 2013, Nature Reviews Molecular Cell Biology.

[11]  G. R. Van de Walle,et al.  The role of BRCA1 in DNA double-strand repair: past and present. , 2013, Experimental cell research.

[12]  Graham Ball,et al.  Targeting XRCC1 deficiency in breast cancer for personalized therapy. , 2013, Cancer research.

[13]  G. Dianov,et al.  Mammalian Base Excision Repair: the Forgotten Archangel , 2013, Nucleic acids research.

[14]  M. Hou,et al.  Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer , 2013, PloS one.

[15]  J. Pascal,et al.  PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. , 2013, Current opinion in structural biology.

[16]  S. Boulton,et al.  Playing the end game: DNA double-strand break repair pathway choice. , 2012, Molecular cell.

[17]  D. Livingston,et al.  Mechanisms of BRCA1 tumor suppression. , 2012, Cancer discovery.

[18]  T. O'Connor,et al.  Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models , 2012, Molecular Cancer Therapeutics.

[19]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[20]  G. Iliakis,et al.  Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. , 2011, Mutation research.

[21]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[22]  R. Hill,et al.  The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? , 2010, Cell cycle.

[23]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[24]  E. Rosen,et al.  Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1* , 2010, The Journal of Biological Chemistry.

[25]  P. Jeggo,et al.  53BP1 promotes ATM activity through direct interactions with the MRN complex , 2010, The EMBO journal.

[26]  Junjie Chen,et al.  BRCA1 and its toolbox for the maintenance of genome integrity , 2010, Nature Reviews Molecular Cell Biology.

[27]  G. Ball,et al.  A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks , 2010, Breast Cancer Research and Treatment.

[28]  K. Valerie,et al.  Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion , 2009, Molecular Cancer Therapeutics.

[29]  Christophe Lemetre,et al.  Artificial Neural Network Based Algorithm for Biomolecular Interactions Modeling , 2009, IWANN.

[30]  E. Alli,et al.  Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. , 2009, Cancer research.

[31]  P. Tassone,et al.  Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo , 2009, Cancer biology & therapy.

[32]  J. Dejmek,et al.  DNA-Dependent Protein Kinase (DNA-PK)–Dependent Cisplatin-Induced Loss of Nucleolar Facilitator of Chromatin Transcription (FACT) and Regulation of Cisplatin Sensitivity by DNA-PK and FACT , 2009, Molecular Cancer Research.

[33]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[34]  A. Nakagawara,et al.  ATM-dependent nuclear accumulation of IKK-α plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin , 2008, Oncogene.

[35]  T. Paull,et al.  Activation and regulation of ATM kinase activity in response to DNA double-strand breaks , 2007, Oncogene.

[36]  Lawrence D True,et al.  Human cancers express a mutator phenotype , 2006, Proceedings of the National Academy of Sciences.

[37]  P. Workman,et al.  Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 , 2005, British Journal of Cancer.

[38]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[39]  J. Nickoloff,et al.  Good Timing in the Cell Cycle for Precise DNA Repair by BRCA1 , 2005, Cell cycle.

[40]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[41]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[42]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[43]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[44]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Venkatraman,et al.  BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.

[46]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[47]  I. Ellis,et al.  Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer , 2013, Breast Cancer Research and Treatment.

[48]  Y. Shiloh,et al.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. , 2013, Nature reviews. Molecular cell biology.

[49]  D. Livingston,et al.  Mechanisms of BRCA 1 Tumor Suppression , 2012 .

[50]  N. Curtin,et al.  Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination , 2011, Cancer Chemotherapy and Pharmacology.

[51]  M C Berenbaum,et al.  Criteria for analyzing interactions between biologically active agents. , 1981, Advances in cancer research.

[52]  J. Ford,et al.  BRCA 1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2022 .